Leerink Partnrs Weighs in on Hims & Hers Health, Inc.’s Q2 2024 Earnings (NYSE:HIMS)

Hims & Hers Health, Inc. (NYSE:HIMS) – Equities researchers at Leerink Partnrs lifted their Q2 2024 earnings per share (EPS) estimates for shares of Hims & Hers Health in a report issued on Tuesday, May 7th. Leerink Partnrs analyst M. Cherny now expects that the company will earn $0.05 per share for the quarter, up from their prior forecast of $0.02. Leerink Partnrs currently has a “Market Perform” rating on the stock. The consensus estimate for Hims & Hers Health’s current full-year earnings is $0.11 per share. Leerink Partnrs also issued estimates for Hims & Hers Health’s Q3 2024 earnings at $0.05 EPS, FY2024 earnings at $0.18 EPS, FY2025 earnings at $0.29 EPS, FY2026 earnings at $0.45 EPS and FY2027 earnings at $0.67 EPS.

HIMS has been the subject of a number of other reports. TheStreet upgraded Hims & Hers Health from a “d” rating to a “c” rating in a report on Monday, March 4th. Canaccord Genuity Group started coverage on shares of Hims & Hers Health in a report on Wednesday, April 10th. They set a “buy” rating and a $20.00 target price on the stock. SVB Leerink assumed coverage on shares of Hims & Hers Health in a research note on Monday, February 26th. They set a “market perform” rating and a $10.00 price objective on the stock. Canaccord Genuity Group assumed coverage on Hims & Hers Health in a report on Wednesday, April 10th. They set a “buy” rating and a $20.00 target price for the company. Finally, Truist Financial boosted their price objective on Hims & Hers Health from $10.00 to $13.00 and gave the company a “hold” rating in a research report on Tuesday, February 27th. Six analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $15.07.

Hims & Hers Health Stock Performance

NYSE:HIMS opened at $12.16 on Thursday. The stock has a 50-day simple moving average of $14.01 and a 200 day simple moving average of $10.39. Hims & Hers Health has a one year low of $5.65 and a one year high of $17.16. The company has a market capitalization of $2.61 billion, a price-to-earnings ratio of -107.91 and a beta of 0.97.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, May 6th. The company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of $0.02 by $0.03. The firm had revenue of $278.20 million for the quarter, compared to the consensus estimate of $270.37 million. Hims & Hers Health had a negative net margin of 2.70% and a negative return on equity of 7.21%. The firm’s revenue was up 45.8% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.05) EPS.

Insider Activity

In other Hims & Hers Health news, insider Soleil Boughton sold 4,080 shares of Hims & Hers Health stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $10.03, for a total value of $40,922.40. Following the transaction, the insider now owns 154,345 shares in the company, valued at $1,548,080.35. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other Hims & Hers Health news, insider Irene Becklund sold 2,747 shares of Hims & Hers Health stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $12.08, for a total transaction of $33,183.76. Following the completion of the sale, the insider now owns 5,494 shares of the company’s stock, valued at approximately $66,367.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Soleil Boughton sold 4,080 shares of the business’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $10.03, for a total transaction of $40,922.40. Following the transaction, the insider now owns 154,345 shares in the company, valued at $1,548,080.35. The disclosure for this sale can be found here. In the last quarter, insiders sold 736,191 shares of company stock worth $9,733,700. Corporate insiders own 31.63% of the company’s stock.

Institutional Trading of Hims & Hers Health

Institutional investors have recently bought and sold shares of the company. Graham Capital Management L.P. raised its position in Hims & Hers Health by 39.4% during the third quarter. Graham Capital Management L.P. now owns 340,338 shares of the company’s stock valued at $2,141,000 after acquiring an additional 96,277 shares in the last quarter. Swiss National Bank grew its holdings in Hims & Hers Health by 9.2% during the third quarter. Swiss National Bank now owns 309,200 shares of the company’s stock valued at $1,945,000 after purchasing an additional 26,100 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Hims & Hers Health by 3.1% in the third quarter. Vanguard Group Inc. now owns 14,126,744 shares of the company’s stock valued at $88,857,000 after purchasing an additional 428,671 shares during the period. Bank of New York Mellon Corp raised its position in shares of Hims & Hers Health by 11.5% in the third quarter. Bank of New York Mellon Corp now owns 564,501 shares of the company’s stock valued at $3,551,000 after purchasing an additional 58,288 shares during the period. Finally, Must Asset Management Inc. acquired a new stake in shares of Hims & Hers Health in the third quarter worth $1,596,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.